Log in

NASDAQ:CBPO - China Biologic Products Stock Price, Forecast & News

$117.00
+0.30 (+0.26 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$116.69
Now: $117.00
$117.90
50-Day Range
$113.00
MA: $116.05
$117.14
52-Week Range
$70.30
Now: $117.00
$119.44
Volume106,276 shs
Average Volume67,454 shs
Market Capitalization$4.61 billion
P/E Ratio29.10
Dividend YieldN/A
Beta1.15
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBPO
CUSIPN/A
Phone86-10-6598-3111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$466.88 million
Cash Flow$5.10 per share
Book Value$55.68 per share

Profitability

Net Income$128.06 million

Miscellaneous

Employees2,187
Market Cap$4.61 billion
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive CBPO News and Ratings via Email

Sign-up to receive the latest news and ratings for CBPO and its competitors with MarketBeat's FREE daily newsletter.


China Biologic Products (NASDAQ:CBPO) Frequently Asked Questions

What is China Biologic Products' stock symbol?

China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO."

How were China Biologic Products' earnings last quarter?

China Biologic Products Holdings Inc (NASDAQ:CBPO) released its quarterly earnings results on Wednesday, November, 13th. The biopharmaceutical company reported $1.40 EPS for the quarter, topping analysts' consensus estimates of $0.88 by $0.52. The biopharmaceutical company had revenue of $136.10 million for the quarter. China Biologic Products had a net margin of 31.22% and a return on equity of 9.79%. The firm's quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.96 earnings per share. View China Biologic Products' Earnings History.

When is China Biologic Products' next earnings date?

China Biologic Products is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for China Biologic Products.

What price target have analysts set for CBPO?

2 equities research analysts have issued 1-year price objectives for China Biologic Products' shares. Their forecasts range from $62.00 to $88.00. On average, they expect China Biologic Products' stock price to reach $75.00 in the next year. This suggests that the stock has a possible downside of 35.9%. View Analyst Price Targets for China Biologic Products.

What is the consensus analysts' recommendation for China Biologic Products?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for China Biologic Products in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for China Biologic Products.

Has China Biologic Products been receiving favorable news coverage?

News coverage about CBPO stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. China Biologic Products earned a news impact score of 1.8 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for China Biologic Products.

Are investors shorting China Biologic Products?

China Biologic Products saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 609,900 shares, a decrease of 17.4% from the September 30th total of 738,400 shares. Based on an average daily volume of 150,900 shares, the short-interest ratio is presently 4.0 days. Currently, 2.9% of the company's stock are sold short. View China Biologic Products' Current Options Chain.

Who are some of China Biologic Products' key competitors?

What other stocks do shareholders of China Biologic Products own?

Based on aggregate information from My MarketBeat watchlists, some companies that other China Biologic Products investors own include Lexicon Pharmaceuticals (LXRX), Sarepta Therapeutics (SRPT), Amgen (AMGN), Biogen (BIIB), The Carlyle Group (CG), Gilead Sciences (GILD), GSI Technology (GSIT), Activision Blizzard (ATVI), Broadcom (AVGO) and Netflix (NFLX).

Who are China Biologic Products' key executives?

China Biologic Products' management team includes the folowing people:
  • Mr. Ming Yang, Chief Financial Officer (Age 47)
  • Mr. Ming Yin, Sr. VP (Age 41)
  • Ms. Zhijing Liu, Corp. VP (Age 65)
  • Mr. Gang Yang, Corp. VP & GM of Guizhou Taibang (Age 54)
  • Dr. Bing Li Ph.D., CEO & Director (Age 51)

Who are China Biologic Products' major shareholders?

China Biologic Products' stock is owned by a number of of institutional and retail investors. Top institutional investors include York Capital Management Global Advisors LLC (2.67%), Nikko Asset Management Americas Inc. (0.33%), Man Group plc (0.17%), State Street Corp (0.14%), California Public Employees Retirement System (0.13%) and Voloridge Investment Management LLC (0.06%). View Institutional Ownership Trends for China Biologic Products.

Which major investors are selling China Biologic Products stock?

CBPO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, York Capital Management Global Advisors LLC, Point72 Asset Management L.P., Tower Research Capital LLC TRC, Barclays PLC, First Trust Advisors LP and SG Americas Securities LLC. View Insider Buying and Selling for China Biologic Products.

Which major investors are buying China Biologic Products stock?

CBPO stock was acquired by a variety of institutional investors in the last quarter, including Man Group plc, Voloridge Investment Management LLC, Robeco Institutional Asset Management B.V., California Public Employees Retirement System, Nikko Asset Management Americas Inc., State Street Corp and Paradice Investment Management LLC. View Insider Buying and Selling for China Biologic Products.

How do I buy shares of China Biologic Products?

Shares of CBPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is China Biologic Products' stock price today?

One share of CBPO stock can currently be purchased for approximately $117.00.

How big of a company is China Biologic Products?

China Biologic Products has a market capitalization of $4.61 billion and generates $466.88 million in revenue each year. The biopharmaceutical company earns $128.06 million in net income (profit) each year or $4.02 on an earnings per share basis. China Biologic Products employs 2,187 workers across the globe.View Additional Information About China Biologic Products.

What is China Biologic Products' official website?

The official website for China Biologic Products is http://www.chinabiologic.com/.

How can I contact China Biologic Products?

China Biologic Products' mailing address is 18TH FL JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD CHAOYANG DISTRICT, BEIJING F4, 100125. The biopharmaceutical company can be reached via phone at 86-10-6598-3111 or via email at [email protected]


MarketBeat Community Rating for China Biologic Products (NASDAQ CBPO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  334 (Vote Outperform)
Underperform Votes:  427 (Vote Underperform)
Total Votes:  761
MarketBeat's community ratings are surveys of what our community members think about China Biologic Products and other stocks. Vote "Outperform" if you believe CBPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Featured Article: Hedge Funds Explained

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel